Reviewing Merrimack Pharmaceuticals (MACK) & Its Peers
Merrimack Pharmaceuticals (NASDAQ: MACK) is one of 189 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Merrimack Pharmaceuticals to related businesses based on the strength of its institutional ownership, earnings, dividends, risk, profitability, valuation and analyst recommendations.
Earnings & Valuation
This table compares Merrimack Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Merrimack Pharmaceuticals||$144.27 million||-$151.74 million||-1.45|
|Merrimack Pharmaceuticals Competitors||$217.29 million||-$39.39 million||-66.72|
This table compares Merrimack Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Merrimack Pharmaceuticals Competitors||-3,262.46%||-525.97%||-39.31%|
Volatility & Risk
Merrimack Pharmaceuticals has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Merrimack Pharmaceuticals’ competitors have a beta of 1.56, meaning that their average stock price is 56% more volatile than the S&P 500.
This is a summary of current ratings for Merrimack Pharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Merrimack Pharmaceuticals Competitors||539||2455||6648||125||2.65|
Merrimack Pharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 41.78%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.66%. Given Merrimack Pharmaceuticals’ higher probable upside, research analysts plainly believe Merrimack Pharmaceuticals is more favorable than its competitors.
Institutional and Insider Ownership
52.6% of Merrimack Pharmaceuticals shares are held by institutional investors. Comparatively, 49.4% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 8.5% of Merrimack Pharmaceuticals shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Merrimack Pharmaceuticals competitors beat Merrimack Pharmaceuticals on 7 of the 12 factors compared.
About Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.
Receive News & Ratings for Merrimack Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.